Smart bombs versus blunderbusses: High-dose chemotherapy for breast cancer

Lancet

Volumn 364, Issue 9442, 2004, Pages 1299-1300

  Crown, John ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

AUTOGRAFT; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; DISEASE COURSE; DRUG MEGADOSE; HUMAN; NOTE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; STEM CELL TRANSPLANTATION;

EID: 5044219894     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17207-3     Document Type: Note

References (10)

1. Weiss RB, Woolf SH, Demakos E. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol. 21:2003;1825-1835
2. Davidson NE. Out of the courtroom and into the clinic. J Clin Oncol. 10:1992;517-519
3. Hortobagyi GN. What is the role of high-dose chemotherapy in the era of targeted therapies. J Clin Oncol. 22:2004;2263-2266
4. Weiss RB, Gill GG, Hudis CA. An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications. J Clin Oncol. 19:2001;2771-2777
5. Zander AR, Kroger N, Schmoor C, et al. High-dose chemotherapy with autologous haematopoietic stem cell support versus standard dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol. 22:2004;2273-2283
6. Nitz UA, Frick M, Mohrmann S, et al. Tandem high dose chemotherapy versus dose-dense conventional chemotherapy for patients with high risk breast cancer: interim results from a multi-centre phase III trial. Proc Am Soc Clin Oncol 2003; 22: 832a (abstr).
7. Crown J, Perey L, Lind M, et al. Superiority of tandem high-dose chemotherapy (HDC) versus optimized conventionally-dosed chemotherapy (CDC) in patients (pts) with metastatic breast cancer (MBC): the International Randomized Breast Cancer Dose Intensity Study (IBDIS 1). Proc Am Soc Clin Oncol 2003; 22: 23a (abstr).
8. Farquhar C, Basser Hetrick S, Lethaby AR, Marjoribanks J. High-dose chemotherapy and autologous bone marrow or stem-cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. In: The Cochrane Library, Issue 1, 2003, Oxford Update Software.
9. Farquhar C, Basser R, Marjoribanks J, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. In: The Cochrane Library, Issue 1, 2003, Oxford Update Software.
10. Pegram M, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst. 19:2004;759-769